PDCD1 and breast carcinoma: Approval of the first immunotherapies in mTNBC, the checkpoint inhibitors pembrolizumab (blocking antibody against programmed death-ligand 1/PD-L1) [3] and atezolizumab (blocking antibody against programmed cell death protein-1/PD-1) [4], generated enthusiasm for the use of immunotherapies in breast cancer.